Understanding virologic heterogeneity in chronic hepatitis B treatment.
作者信息
Luo Renqi, Ran Xue, Sun Ruihan
机构信息
Huazhong Agricultural University, Wuhan, Hubei, China.
Dezhou Municipal Hospital, Dezhou, Shandong, China.
出版信息
JHEP Rep. 2024 Oct 19;7(2):101249. doi: 10.1016/j.jhepr.2024.101249. eCollection 2025 Feb.
Abstract
摘要
相似文献
1
Understanding virologic heterogeneity in chronic hepatitis B treatment.了解慢性乙型肝炎治疗中的病毒学异质性。
JHEP Rep. 2024 Oct 19;7(2):101249. doi: 10.1016/j.jhepr.2024.101249. eCollection 2025 Feb.
2
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.蓝病毒单药治疗慢性 HDV 患者：一项 III 期随机试验中至第 96 周的疗效和安全性结果。
J Hepatol. 2024 Oct;81(4):621-629. doi: 10.1016/j.jhep.2024.05.001. Epub 2024 May 9.
3
Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response.初治乙型肝炎患者的恩替卡韦长期真实世界治疗：基线乙型肝炎病毒DNA和乙型肝炎表面抗原水平可预测病毒学应答。
Korean J Intern Med. 2017 Jul;32(4):636-646. doi: 10.3904/kjim.2016.096. Epub 2016 Nov 4.
4
Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B.慢性乙型肝炎 C 基因型患者恩替卡韦治疗期间病毒抑制不足的临床病程。
Dig Liver Dis. 2013 Jul;45(7):600-5. doi: 10.1016/j.dld.2012.12.013. Epub 2013 Jan 18.
5
Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.在对拉米夫定产生临床或病毒学耐药的HBeAg阴性慢性乙型肝炎病毒感染成人患者中，比较阿德福韦与拉米夫定联合用药和阿德福韦单药治疗：一项回顾性、多中心、非随机、开放标签研究。
Clin Ther. 2008 Feb;30(2):317-23. doi: 10.1016/j.clinthera.2008.02.012.
6
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.台湾地区慢性丙型肝炎与乙型肝炎合并感染患者接受雷迪帕韦/索磷布韦治疗：治疗后 108 周随访结果。
Clin Infect Dis. 2022 Aug 31;75(3):453-459. doi: 10.1093/cid/ciab971.
7
Continuous long-term entecavir therapy in naïve chronic hepatitis B patients showing partial virologic response.初治慢性乙型肝炎患者获得部分病毒学应答后持续长期恩替卡韦治疗。
Gut Liver. 2013 Nov;7(6):712-8. doi: 10.5009/gnl.2013.7.6.712. Epub 2013 Aug 14.
8
Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.恩替卡韦单药长期治疗对初治慢性乙型肝炎患者的疗效，这些患者对恩替卡韦呈现部分病毒学应答
Clin Mol Hepatol. 2015 Mar;21(1):24-31. doi: 10.3350/cmh.2015.21.1.24. Epub 2015 Mar 25.
9
Virologic Response at 12 Months Predicts Lower Hepatocellular Carcinoma Risk in Genotype D Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogues.12个月时的病毒学应答可预测接受核苷（酸）类似物治疗的D型慢性乙型肝炎患者肝细胞癌风险较低。
J Clin Med. 2025 Apr 11;14(8):2618. doi: 10.3390/jcm14082618.
10
Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B.预测替诺福韦单药挽救治疗对多药耐药慢性乙型肝炎的病毒学应答。
J Med Virol. 2016 Jun;88(6):1027-34. doi: 10.1002/jmv.24427. Epub 2015 Nov 19.
本文引用的文献
1
Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy.慢性乙型肝炎中不同的病毒学轨迹揭示了对核苷（酸）类似物治疗反应的异质性。
JHEP Rep. 2024 Oct 9;7(1):101229. doi: 10.1016/j.jhepr.2024.101229. eCollection 2025 Jan.
2
Association of HBV serological markers with host antiviral immune response relevant hepatic inflammatory damage in chronic HBV infection.HBV 血清学标志物与慢性 HBV 感染中宿主抗病毒免疫反应相关肝炎症损伤的关系。
J Med Virol. 2024 Apr;96(4):e29569. doi: 10.1002/jmv.29569.
3
Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs.替诺福韦艾拉酚胺治疗对既往核苷（酸）类似物治疗无应答的慢性乙型肝炎患者的疗效。
J Gastroenterol. 2021 Nov;56(11):1008-1021. doi: 10.1007/s00535-021-01826-8. Epub 2021 Oct 1.
4
Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review.患者对慢性乙型肝炎和丙型肝炎抗病毒治疗的依从性：系统评价。
Ann Hepatol. 2013 May-Jun;12(3):380-91.
Zotero 插件